Methylprednisolone Acetate Injectable Suspension Recall: Sterility Assurance
Teva Pharmaceuticals USA is recalling Methylprednisolone Acetate Injectable Suspension USP 40 mg/mL in single-dose and multi-dose vials nationwide due to lack of assurance of sterility.
What this means for you
Illness, injury, or structural failure has been reported. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: This is an FDA Class II recall for a sterile injectable drug product with potential for serious health consequences if contaminated product is administered. Lack of sterility assurance in an injectable pharmaceutical meets the Severe criterion for injectable medications with potential for harm, even absent reported hospitalizations in the source text.
Plain-English summary
Teva Pharmaceuticals USA is recalling Methylprednisolone Acetate Injectable Suspension USP, 40 mg/mL, packaged in 1 mL single-dose vials (NDC 0703-0031-01), 5 mL multi-dose vials (NDC 0703-0043-01), and 10 mL multi-dose vials (NDC 0703-0045-01). The recall affects approximately 193,845 vials distributed nationwide, including Puerto Rico.
The reason for the recall is lack of assurance of sterility. The affected lot numbers are: 31328455B (exp. 09/2021), 31329340B (exp. 12/2021), 31329439B (exp. 01/2022), 31328347B (exp. 07/2021) for 1 mL vials; 31328321B (exp. 07/2021) for 5 mL vials; and 31328368B, 31328394B (exp. 07/2021), 31328699B (exp. 09/2021), 31328834B (exp. 10/2021), and 31329286B (exp. 12/2021) for 10 mL vials.
Healthcare providers and patients who have received this product should contact their pharmacy or healthcare provider for guidance. Patients should not stop using their medication without consulting their healthcare provider.
The recalled product
- Product
- Methylprednisolone Acetate Injectable Suspension USP, 40 mg/mL, packaged in a) 1 mL Single-Dose vials (0703-0031-01), and b) 5mL Multi Dose Vials (NDC 0703-0043-01), and c) 10 mL Multi-Dose Vials (NDC 0703-0045-01), Rx only, TEVA PHARMACEUTICALS USA, INC. North Wales, PA 19454.
- Manufacturer
- Teva Pharmaceuticals USA
- Affected units
- 193,845
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (15)
- Lot #: a) 31328455B
- exp. date 09/2021
- 31329340B
- exp. date 12/2021
- 31329439B
- exp. date 01/2022
- 31328347B
- exp. date 07/2021 b) 31328321B
- exp. date 07/2021
- c) 31328368B
- 31328394B
- 31328699B
- 31328834B
- exp. date 10/2021
- 31329286B
Distribution
Part of a larger recall action
This product is one of 19 recalled by Teva Pharmaceuticals USA under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 19 products in this recall →Related recalls
Same manufacturer · Teva Pharmaceuticals USA
See all →- ModerateDoxylamine Succinate and Pyridoxine Hydrochloride Tablets Recalled for Failed Dissolution
FDA (Drugs) · 2022-02-09
- LowPrescription Drug Recall: Mimvey Mislabeling by Teva Pharmaceuticals
FDA (Drugs) · 2022-02-09
- ModerateTretinoin Capsules 10 mg Recalled for Failed Dissolution Specifications
FDA (Drugs) · 2022-02-09
- LowMimvey Estradiol/Norethindrone Prescription Drug Mislabeling Recall
FDA (Drugs) · 2022-02-09
- ModerateBrinzolamide Ophthalmic Suspension recalled for defective container caps
FDA (Drugs) · 2022-01-26
Same hazard · lack of sterility
See all →- HighRohto Cooling Eye Drops Max Strength Recalled Due to Sterility Concerns
FDA (Drugs) · 2026-07-29
- HighRohto Cooling Eye Drops Recalled Due to Lack of Assurance of Sterility
FDA (Drugs) · 2026-07-29
- SevereCleviprex Injectable Emulsion Recall Due to Sterility Assurance Concerns
FDA (Drugs) · 2026-07-22
- SeverePemetrexed for Injection recalled due to lack of sterility assurance
FDA (Drugs) · 2026-07-15
- SevereAzacitidine for Injection Recalled for Lack of Sterility Assurance
FDA (Drugs) · 2026-07-15